Pfizer, Kyowa Hakko Kirin partner on immuno-oncology study
- Pfizer and Kyowa Hakko Kirin are exploring the therapeutic potential of combining two antibodies—one developed by each company—to treat solid tumors.
- The two companies will co-fund the clinical study project.
- The two therapies that are being studied in combination include Pfizer’s PF-05082566, a fully humanized mAB, and Kyowa’s Mogamulizumab.
Two may be better than one—at least when it comes to creating powerful oncologic treatments.
Pfizer's PF-05082566 is currently being evaluated as a single agent in a phase I study for treatment of multiple types of tumors. It is also being studied in combination with Rituximab.
Kyowa’s Mogamulizumab was launched in Japan in 2012 for treatment of relapsed/refractory CCR4-positive adult T-cell leukemia-lymphoma. There are also additional ongoing clinical trials of Mogamulizumab for various types of blood cancer.
The goal is to turn up the volume on outcomes by combining these two therapies.